May 15, 2020
BioInvent Expands Anti-TNFR2 Program by Selecting Second Monoclonal Antibody for Further Development
May 05, 2020
Therapeutic Solutions International Leverages Filed and Issued Intellectual Property to Develop COVID-19 Nutraceutical Candidate: QuadraMune(TM)
Mar 23, 2020
Global Hidradenitis Suppurativa (HS) Industry Assessment, 2020 Featuring InflaRx, Novartis Pharma, Incyte Corp, UCB Biopharma, and Janssen Pharma
Jan 08, 2020
Therapeutic Solutions International Reports Inhibition of Microglial Activation with NeuroStilbene
Dec 06, 2019
FDA Approves Amgen's AVSOLA(TM) (infliximab-axxq), For The Same Indications As Remicade® (infliximab)
Mar 28, 2019
CIMZIA® (certolizumab pegol) is Now the First and Only U.S. FDA-Approved Treatment for Non-Radiographic Axial Spondyloarthritis
Mar 21, 2019
BioInvent Unveils Broad Anti-TNFR2 Program to Treat Solid Tumors
Mar 11, 2019
Arthritis & Rheumatology Publishes the First Randomized Placebo-Controlled Study Over 52 Weeks in Non-Radiographic Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol)
Mar 01, 2019
New Data Affirms Strength of UCB Immuno-Dermatology Portfolio
Jan 14, 2019
Janssen's Stelara and Pfizer's Xeljanz Battle Takeda's Entyvio to Claim the Preferred Alternate Mechanism of Action Position in Inflammatory Bowel Disease Patients Who Are Being Switched from Their Current Treatment
Nov 01, 2018
Investigation Report on China's Infliximab (Johnson & Johnson) Market, 2018-2022
Aug 10, 2018
TNF Inhibitors Market is Anticipated to Reach US$ 53,745.37 Mn by 2026, Says TMR
Jul 06, 2018
Creative Medical Technology Holdings Aims to Treat Cancer Associated Wasting (Cachexia) Using AmnioStem Universal Donor Stem Cell
May 29, 2018
UCB Announces the Approval of CIMZIA® (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
May 16, 2018
CIMZIA® (certolizumab pegol) is the First Therapy to Demonstrate Positive Results in a 52-week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study
Apr 02, 2018
Prestigious Paul Ehrlich Award Bestowed Upon Araim Pharmaceuticals Founder, Anthony Cerami
Mar 16, 2018
Tumor Necrosis Factor Inhibitors Drug Market, 2024 - Humira and Remicade Have Made it to the List of Blockbuster Drugs of 2017 with Global Sales of US$ 17.6 Billion
Feb 16, 2018
UCB Advances Psoriasis Pipeline with Positive Data at American Academy of Dermatology Annual Meeting (AAD 2018)
Nov 06, 2017
UCB Presents New Findings Advancing Patient Care for Chronic Inflammatory Diseases and Osteoporosis at 2017 ACR/ARHP Annual Meeting
Oct 31, 2017
TNF Inhibitors 2017 - A Pipeline Analysis Report - By Therapy, Roa & Molecule Type